Erythropoiesis-Stimulating Agents for Cancer-Associated Anemia

An update to 2010 guidelines

Sponsoring Organizations: American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO)

Background

Given the excess risks for thromboembolic events and adverse effects on cancer outcomes associated with erythropoiesis-stimulating agents (ESAs), an expert panel convened by ASH and ASCO has updated 2010 guidelines for ESA use in adult cancer patients with anemia. The panel conducted a systematic literature review of 15 meta-analyses and 2 randomized, controlled trials from 2010 to 2018. Areas of interest included ESA safety for metastatic breast cancer patients, the role of iron, and comparative effectiveness of an epoetin biosimilar formulation.

Key Points

ESAs can be used when the underlying cancer is incurable and anemi…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Erythropoiesis-Stimulating Agents for Cancer-Associated Anemia

Topics

Background

Key Points

Reviewing Author